FKBP3 aggravates the malignant phenotype of diffuse large B‐cell lymphoma by PARK7‐mediated activation of Wnt/β‐catenin signalling
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Xiaojing Xing und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Breast Cancer, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute), Shenyang, Chin…. Hauptthemen laut MEDLINE: beta Catenin, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, General Program of the National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Diffuse large B‐cell lymphoma (DLBCL) is difficult to treat due to the high recurrence rate and therapy intolerance, so finding potential therapeutic targets for DLBCL is critical. FK506‐binding protein 3 (FKBP3) contributes to the progression of various cancers and is highly expressed in DLBCL, but the role of FKBP3 in DLBCL and its mechanism are not clear. Our study demonstrated that FKBP3 aggravated the proliferation and stemness of DLBCL cells, and tumour growth in a xenograft mouse model. The interaction between FKBP3 and parkinsonism associated deglycase (PARK7) in DB cells was found using co‐immunoprecipitation assay. Knockdown of FKBP3 enhanced the degradation of PARK7 through increasing its ubiquitination modification. Forkhead Box O3 (FOXO3) belongs to the forkhead family of transcription factors and inhibits DLBCL, but the underlying mechanism has not been reported. We found that FOXO3 bound the promoter of FKBP3 and then suppressed its transcription, eventually weakening DLBCL. Mechanically, FKBP3 activated Wnt/β‐catenin signalling pathway mediated by PARK7. Together, FKBP3 increased PARK7 and then facilitated the malignant phenotype of DLBCL through activating Wnt/β‐catenin pathway. These results indicated that FKBP3 might be a potential therapeutic target for the treatment of DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Breast Cancer, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute), Shenyang, China.
- Department of Pathology, Shenyang Medical College, Shenyang, China.
- Department of Scientific Research and Academic, Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute), Shenyang, China.
- State Key Laboratory of Robotics, Shenyang Institute of Automation, Chinese Academy of Sciences, Shenyang, China.
- Institutes for Robotics and Intelligent Manufacturing, Chinese Academy of Sciences, Shenyang, China.
ORCID-Profile: Xiaojing Xing
Förderung
- Fundamental Research Funds for the Central Universities
- General Program of the National Natural Science Foundation of China
- National Natural Science Foundation of China
- Provincial and Ministerial Science Foundation (Millions of Talents Project of Liaoning Province in 2019)
Zitieren
APA
Xing, X., Liu, M., Wang, X., Guo, Q., Wang, H., & Wang, W. (2024). FKBP3 aggravates the malignant phenotype of diffuse large B‐cell lymphoma by PARK7‐mediated activation of Wnt/β‐catenin signalling. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18041
Vancouver
Xing X, Liu M, Wang X, Guo Q, Wang H, Wang W. FKBP3 aggravates the malignant phenotype of diffuse large B‐cell lymphoma by PARK7‐mediated activation of Wnt/β‐catenin signalling. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18041
BibTeX
@article{Xing2024,
author = {Xing, Xiaojing and Liu, Meichen and Wang, Xuguang and Guo, Qianxue and Wang, Hongyue and Wang, Wenxue},
title = {FKBP3 aggravates the malignant phenotype of diffuse large B‐cell lymphoma by PARK7‐mediated activation of Wnt/β‐catenin signalling},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18041}
}
EUVIMED